Status:
RECRUITING
Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer
Lead Sponsor:
Fudan University
Conditions:
Breast Cancer
Sentinel Lymph Node
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Sentinel Lymph Node Biopsy (SLNB) is a common surgical treatment for breast cancer and a primary method for assessing the pathological status of axillary lymph nodes. Precise intraoperative detection ...
Detailed Description
In recent years, the incidence of breast cancer in China has risen rapidly. Over the past two decades, the annual average incidence rate has increased from 15 per 100,000 to about 30 per 100,000. In f...
Eligibility Criteria
Inclusion
- Age 18 years and older (inclusive)
- Female
- Preoperative pathology confirmed invasive breast carcinoma or ductal carcinoma in situ
- Scheduled for sentinel lymph node biopsy
- Capable of and willing to provide informed consent
Exclusion
- Patients with a confirmed allergy to methylene blue or sodium citrate tracers
- Pregnant or lactating women
- Patients unwilling to participate in the clinical study
Key Trial Info
Start Date :
January 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
709 Patients enrolled
Trial Details
Trial ID
NCT06911528
Start Date
January 30 2024
End Date
December 31 2025
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032